Migraine, one of the leading global causes of disability, presents a complex challenge in aviation medicine. Headache is the fourth most common cause of in-flight pilot incapacitation, and cockpit-related exposures—including hypobaric hypoxia, low humidity, circadian disruption, and, in military aviation, sustained +Gz loading—may lower the migraine threshold. At the same time, aeromedical regulations restrict the medication options available to treating neurologists. This focused narrative review synthesizes pilot-specific clinical evidence and the principal regulatory documents issued by the International Civil Aviation Organization (ICAO Annex 1 and Doc 8984) and the U.S. Federal Aviation Administration (FAA Aviation Medical Examiner Guide) to provide neurologists with a practical framework for managing pilots with migraine. Simple analgesics, including acetaminophen/paracetamol, ibuprofen, naproxen, and aspirin at standard doses, are permitted under both ICAO and FAA frameworks. Triptans are permitted by the FAA after a 24- to 48-hour ground-observation period, whereas gepants such as ubrogepant and rimegepant require a 48-hour observation period. Beta-adrenergic blockers and calcium channel blockers are accepted preventive agents under both frameworks after a 7-day ground trial, whereas tricyclic antidepressants, topiramate, valproate, opioids, and butalbital-containing compounds are unacceptable. Anti–calcitonin gene-related peptide monoclonal antibodies are now accepted by the FAA after a 7-day ground trial, providing an additional certification-compatible option for pilots with migraine refractory to traditional preventive therapy. Most pilots with migraine can be managed in a manner compatible with continued flight duty when the neurologist selects medications within the applicable aeromedical formulary and documents clinical stability objectively to support certification.
Purpose: The aim of this clinical practice guideline (CPG) from the Korean Headache Society is to provide evidence-based recommendations on the pharmacologic treatment for migraine prevention in adult migraine patients.
Methods The present CPG was developed based on the guideline adaptation methodology through a comprehensive systematic search for literature published between January 2012 and July 2020. The overall quality of the CPGs was assessed using the Korean version of the Appraisal of Guidelines for Research and Evaluation II tool. High-quality CPGs were adapted to make key recommendations in terms of strength (strong or weak) and direction (for or against).
Results The authors selected nine available high-quality guidelines throughout the process of assessment of quality. Regarding oral migraine preventive medications, propranolol, metoprolol, flunarizine, sodium divalproex, and valproic acid are recommended to adult patients with episodic migraines based on high-quality evidence (“strong for”). Topiramate can be recommended for either episodic or chronic migraine (“strong for”). For migraine prevention using calcitonin gene-related peptide monoclonal antibodies, galcanezumab, fremanezumab, erenumab, and eptinezumab are recommended for adult patients with either episodic or chronic migraine on the basis of high-quality evidence (“strong for”). OnabotulinumtoxinA is recommended for adult patients with chronic migraine based on high-quality evidence (“strong for”). Last, frovatriptan, naratriptan, and zolmitriptan are recommended for short-term prevention in women with menstrual migraine (“strong for”).
Conclusion In the present CPG, the authors provide specific, straightforward, and easy-to-implement evidence-based recommendations for pharmacologic migraine prevention. Nevertheless, these recommendations should be applied in real-world clinical practice based on optimal individualization.
Citations
Citations to this article as recorded by
Alcohol-Induced Headache: A Narrative Review Based on Migraine Pathophysiology Woo-Seok Ha Headache and Pain Research.2026; 27(1): 21. CrossRef
Natural Diagnostic Classes of Headache Disorders: Latent Class Analysis of a Population-Based Study Wonwoo Lee, Seok-Jae Heo, Jungyon Yum, Min Kyung Chu Headache and Pain Research.2026; 27(1): 30. CrossRef
Risk of hypertension after CGRP antagonist treatment in migraine: A systematic review and meta‐analysis Kunhee Kim, Kihun Kim, Su‐Yeon Cho, Yujin Kwon, Won Kyu Kim, Chaeseong Lim, Won Ho Cho, Dokyoung Kim, Yun Hak Kim, Tae‐Jin Song Headache: The Journal of Head and Face Pain.2026;[Epub] CrossRef
Real-world effectiveness and safety of CGRP monoclonal antibodies in elderly migraine patients: a Korean multicenter study Soohyun Cho, Mi-Kyoung Kang, Heui-Soo Moon, Mi Ji Lee, Soo-Kyoung Kim, Hong-Kyun Park, Woo-Seok Ha, Min Kyung Chu, Young-Eun Gil, Byung-Su Kim, Soo-Jin Cho The Journal of Headache and Pain.2026;[Epub] CrossRef
Current landscape of migraine care with expert consensus from East Asia Shuu-Jiun Wang, Tsubasa Takizawa, Jiying Zhou, Mi Ji Lee, Daisuke Danno, Min Kyung Chu, Byung-Kun Kim The Journal of Headache and Pain.2026;[Epub] CrossRef
The Impact of Limited Insurance Coverage on Long-Term Persistence with Anti-CGRP Monoclonal Antibody Therapy: A Multicenter Real-World Study in Korea Mi-Kyoung Kang, Jong-Hee Sohn, Myoung-Jin Cha, Yoo Hwan Kim, Yooha Hong, Hee-Jin Im, Soo-Jin Cho Headache and Pain Research.2026; 27(2): 145. CrossRef
One-Year Compliance After Calcitonin Gene-Related Peptide Monoclonal Antibody Therapy for Migraine Patients in a Real-World Setting: A Multicenter Cross-Sectional Study Mi-kyoung Kang, Jong-Hee Sohn, Myoung-Jin Cha, Yoo Hwan Kim, Yooha Hong, Hee-Jin Im, Soo-Jin Cho Journal of Clinical Medicine.2025; 14(3): 734. CrossRef
Beyond the Pain: Rethinking Migraine Care with the RELIEF PLAN Approach Sanghyo Ryu Headache and Pain Research.2025; 26(1): 1. CrossRef
Concurrent Extracerebral Vasoconstriction in Patients with Reversible Cerebral Vasoconstriction Syndrome: A Cross-Sectional Study Byung-Su Kim, Sumin Kim, Eunhee Kim, Ick-Mo Chung, Sodam Jung, Yoonkyung Chang, Dong Woo Shin, Tae-Jin Song Journal of Clinical Medicine.2025; 14(13): 4402. CrossRef
Validity of Migraine Diagnoses in Korean National Health Insurance Claims Data Yoonkyung Chang, Soyoun Choi, Byung-Su Kim, Tae-Jin Song Headache and Pain Research.2025; 26(2): 154. CrossRef
Tension-Type Headache and Primary Stabbing Headache: Primary Headaches Beyond Migraine Mi-Kyoung Kang Headache and Pain Research.2025; 26(2): 89. CrossRef
Injection-Based Therapies for Migraine in Older Adults: A Narrative Review of OnabotulinumtoxinA, Greater Occipital Nerve Block, and Anti Calcitonin Gene-Related Peptide Monoclonal Antibodies Mi-Kyoung Kang, Soohyun Cho, Byung-Kun Kim, Heui-Soo Moon, Mi Ji Lee, Soo-Kyoung Kim, Hong-Kyun Park, Min-Kyung Chu, Woo-Seok Ha, Byung-Su Kim, Soo-Jin Cho Journal of Korean Medical Science.2025;[Epub] CrossRef
Use of Antiseizure Medications in Neurological Disorders Beyond Epilepsy Kyung Min Kim, Byung-Su Kim, Hee-Jin Kim, Seung Woo Kim, Kyoungwon Baik, Jin Myoung Seok, Jun-Sang Sunwoo, In-Uk Song, Ho Geol Woo, Eek-Sung Lee, Jin-Man Jung, Kyomin Choi, Yun Ho Choi, Kwang Ik Yang Journal of the Korean Neurological Association.2025; 43(4): 245. CrossRef
A Practical Approach to Headache in Moyamoya Disease Mi-Yeon Eun, Jin-Man Jung, Jay Chol Choi Headache and Pain Research.2025; 26(3): 173. CrossRef
Evolution of Migraine Treatment: Recent Drugs and Clinical Trial Trends Yoon-Kyung Chang, Tae-Jin Song NeuroTrials.2025; 1(1): 7. CrossRef
Clinical Effectiveness and Cost-Effectiveness of Collaborative Treatment With Korean and Western Medicine for Primary Headache Disorders: Protocol for a Multicenter Prospective Observational Study Jaeseung Kim, Jihwan Yun, Linae Kim, Shiva Raj Acharya, Changyon Han, NamKwen Kim JMIR Research Protocols.2025; 14: e82819. CrossRef
Clinical Practice Guideline Recommendations for Post-Acute Sequelae of COVID-19 Jun-Won Seo, Yu Bin Seo, Seong Eun Kim, Yoonjung Kim, Eun Jung Kim, Tark Kim, Taehwa Kim, So Hee Lee, Eunjung Lee, Jacob Lee, Yeong-Hoon Jeong, Yeong Hee Jung, Yu Jung Choi, Joon Young Song Infection & Chemotherapy.2025; 57(4): 478. CrossRef
Kim Byung-Su, Jae Myun Chung, Pil-Wook Chung, Kwang-Yeol Park, Jin-Young Ahn, Heui-Soo Moon, Hong-Kyun Park, Dae Woong Bae, Jong-Geun Seo, Jong-Hee Sohn, Tae-Jin Song
Byung-Su Kim, Byung-Kun Kim, Soo-Kyoung Kim, Jae-Moon Kim, Heui-Soo Moon, Kwang-Yeol Park, Jong-Hee Sohn, Tae-Jin Song, Min Kyung Chu, Myoung-Jin Cha, Soo-Jin Cho, J
Myoung-Jin Cha, Byung-Kun Kim, Byung-Su Kim, Jong-Hee Sohn, Soo-Kyoung Kim, Heui-Soo Moon, Tae-Jin Song, Jae-Moon Kim, Jeong Wook Park, Min Kyung Chu, Kwang-Yeol Park